Imvaggis

Estriol, the active ingredient in Imvaggis, is an estrogen presented as a vaginal formulation for local use. It is employed to alleviate estrogen deficiency symptoms in the vaginal tissues of postmenopausal women, helping to restore moisture and reduce discomfort. It can be administered as a cream or tablet inserted into the vagina, allowing direct tissue exposure with minimal systemic absorption.

GNH USA supplies Imvaggis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Imvaggis (estriol) acts on estrogen receptors in the vaginal epithelium to treat conditions related to estrogen deficiency.

- Atrophic Vaginitis: Improves vaginal dryness and irritation in postmenopausal women. - Dyspareunia: Reduces pain during intercourse caused by estrogen deficiency. - Genitourinary Syndrome of Menopause: Alleviates urinary urgency and frequency associated with menopausal estrogen loss.

Local estrogen therapy may be associated with adverse reactions, most of which are mild and reversible.

Common Side Effects: - Vaginal irritation: mild burning or stinging at the application site. - Increased vaginal discharge: watery or mucous secretion. - Itching: localized pruritus. - Spotting: light vaginal bleeding. - Headache: transient mild headache.

Serious or Rare Side Effects: - Endometrial hyperplasia: abnormal thickening of the uterine lining. - Breast tenderness: persistent pain or swelling. - Thromboembolic events: rare clot formation. - Allergic reaction: rash, swelling, or difficulty breathing.

Before initiating therapy, clinicians should evaluate patient history and monitor for adverse events.

- Assess contraindications: review patient history for estrogen‑dependent neoplasia or thromboembolic disease. - Monitor symptoms: watch for abnormal vaginal bleeding or persistent irritation. - Use lowest effective dose: limit estrogen exposure to the minimum required for symptom relief. - Avoid use in pregnancy: estriol may affect fetal development; pregnancy status should be confirmed. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Estriol may interact with other medications that influence estrogen pathways or hemostasis.

Major Interactions (Avoid): - Combined hormonal contraceptives: may increase overall estrogen load. - Systemic estrogen therapy: risk of excess estrogen exposure. - Anticoagulants: potential increased bleeding risk.

Moderate Interactions (Monitor Closely): - Tamoxifen: may reduce the therapeutic efficacy of estriol. - SSRIs (e.g., fluoxetine): may alter estriol metabolism and plasma levels.